Mindmed Announces First Patient Dosed In Phase 3 Emerge Study Of Mm120 In Major Depressive Disorder (Mdd)
April 15 (Reuters) - Mind Medicine (MindMed) Inc MNMD.O:
MINDMED ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 EMERGE STUDY OF MM120 IN MAJOR DEPRESSIVE DISORDER (MDD)
MIND MEDICINE (MINDMED) INC - TOPLINE DATA EXPECTED IN SECOND HALF OF 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Big Tech’s AI Data Center Power Demands Trigger $15B PJM Auction and a Nuclear SMR Boom

Tradingkey







